Investor's Business Daily on MSN
Kymera rockets, pulling Nurix higher. Does it have the next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...
Paris: French multinational pharmaceutical giant, Sanofi, has announced the completion of its acquisition of Vicebio Ltd.This ...
Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:45 AM ESTCompany ParticipantsJane Pritchett Henderson ...
Morgan Stanley flagged upside risks if pipeline data impresses, Dupixent intellectual property proves more durable, or Eylea HD adoption accelerates. Downside risks include trial setbacks, competitive ...
Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...
Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in patients ...
Sanofi (NASDAQ: SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel ...
The main market opportunities for CD38-targeted immunotherapies lie in multiple myeloma treatment, given its high CD38 expression. With successful therapeutics like daratumumab and isatuximab, ...
Sanofi (NASDAQ: SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel ...
On November 17, 2025 Formycon AG (“Formycon”) announced development of a dupilumab biosimilar, FYB208, referencing Regeneron and Sanofi’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback